0 -0.000283586986137596 -0.000528250268295556 0.000550492384855348 -0.00154026657176696 0.00300824626471447 0.0093138863094212 0.0149411417990535
Sign Up Today X
Thanks for submitting the form.
Stockreport

Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy [Seeking Alpha]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Seeking Alpha
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
soroparvovec (lxo-vec), could become an alternative to the current standard of care, anti-vascular endothelial growth factor (anti-VEGF) injections. The firm has a $30 price target (~209% upside based on Tuesday's close). Analyst Matthew Caufield noted that wet AMD has a prevalence of ~1.5M patients in the U.S. with ~200,000 new cases annually. While these patients rely on anti-VEGF for treatment currently, they have to be given as often as every four to eight weeks, leading to chronic treatment burden and non-compliance. An interim analysis of 26-week phase 2 data found that patients given either dose of lxo-vec saw 90% and 94%, respectively, reductions in annualized anti-VEGF injections. Also, a phase 1 trial showed that one lxo-vec treatment led to aflibercept protein expression maintained through three years. "Ixo-vec utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette," according to [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy [Seeking Alpha]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Seeking Alpha
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
soroparvovec (lxo-vec), could become an alternative to the current standard of care, anti-vascular endothelial growth factor (anti-VEGF) injections. The firm has a $30 price target (~209% upside based on Tuesday's close). Analyst Matthew Caufield noted that wet AMD has a prevalence of ~1.5M patients in the U.S. with ~200,000 new cases annually. While these patients rely on anti-VEGF for treatment currently, they have to be given as often as every four to eight weeks, leading to chronic treatment burden and non-compliance. An interim analysis of 26-week phase 2 data found that patients given either dose of lxo-vec saw 90% and 94%, respectively, reductions in annualized anti-VEGF injections. Also, a phase 1 trial showed that one lxo-vec treatment led to aflibercept protein expression maintained through three years. "Ixo-vec utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette," according to [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS